Daiichi Sankyo

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC

Retrieved on: 
Wednesday, August 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, WCLC, Carcinoma, HER2, Trastuzumab deruxtecan, International Association, Lung cancer, Research, NSCLC, Carboplatin, Lung, EDT, SCLC, MD, Patient, EGFR, Daiichi Sankyo, DXD, ADC, R, Durvalumab, Conference, TSE, JST, Fine chemical, Pharmaceutical industry

Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23) being held September 9-12, 2023.

Key Points: 
  • Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23) being held September 9-12, 2023.
  • “Data at WCLC from four of our DXd antibody drug conjugates in populations across several different subtypes of non-small cell lung cancer and small cell lung cancer continue to demonstrate Daiichi Sankyo’s commitment to creating new standards of care for these patients,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • Executives from Daiichi Sankyo will provide an overview of the WCLC research data and address questions.
  • Highlights of data from Daiichi Sankyo’s DXd ADC portfolio at 2023 WCLC include:

Veeva R&D and Quality Summit Brings Together Biopharma Leaders to Accelerate Innovation

Retrieved on: 
Thursday, August 17, 2023
Cloud, CRISPR, Takeda, Align Biopharma, Bristol Myers Squibb, Amylyx Pharmaceuticals, Veeva Systems, Patient, GxP, Daiichi Sankyo, Jazz Pharmaceuticals, Merck, CRISPR Therapeutics, NYSE, ChromeOS, Safety, Pharmaceutical industry, Amgen, Sanofi

PLEASANTON, Calif.,  Aug. 17, 2023  /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that visionaries from Amgen, Bristol Myers Squibb, Daiichi Sankyo, Merck, and Takeda will be keynote speakers at the upcoming 2023 Veeva R&D and Quality Summit in Boston on Sept. 13 and 14. Biopharma leaders will share how new strategies and technology across clinical, regulatory, safety, and quality are moving the industry forward with speed and efficiency.

Key Points: 
  • Biopharma leaders will share how new strategies and technology across clinical, regulatory, safety, and quality are moving the industry forward with speed and efficiency.
  • As one of the largest life sciences events, Veeva R&D and Quality Summit will bring together more than 2,000 executives to share learnings across more than 90 sessions.
  • Additional featured keynotes and sessions include:
    Amgen shares its journey to simplify and improve the user experience across GxP quality management.
  • "Veeva R&D and Quality Summit brings together life sciences leaders from across the globe to learn, share insights, and innovate," said Jim Reilly, vice president of Veeva Development Cloud strategy.

VANFLYTA® (quizartinib) Now Available from Onco360

Retrieved on: 
Wednesday, August 9, 2023
FDA, Pharmaceutical, Health, Oncology, Maintenance, ITD, Pharmacy, HSCT, Acute myeloid leukemia, AML, Specialty pharmacy, Patient, Risk, Daiichi Sankyo, HR, FLT3, American Cancer Society, United, Leukemia, Death, Caregiver, Pharmaceutical industry, Nursing

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Daiichi Sankyo to be a specialty pharmacy partner for VANFLYTA® (quizartinib).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Daiichi Sankyo to be a specialty pharmacy partner for VANFLYTA® (quizartinib).
  • VANFLYTA is not indicated as a maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.
  • “Onco360 is grateful for the opportunity to partner with the team at Daiichi Sankyo and become a specialty pharmacy provider for VANFLYTA patients,” said Benito Fernandez, Chief Commercial Officer.
  • It is the first and only FLT3 inhibitor to be approved by the FDA specifically for FLT3-ITD positive AML across the three phases of treatment – induction, consolidation, and maintenance in patients without transplant.

VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Neutropenia, REMS, Maintenance, Hypermagnesemia, Cardiac arrest, Febrile neutropenia, Hypophosphatemia, Magnesium, Diarrhea, Mitigation, Hypocalcemia, Pharmacy, Food, QT interval, Indigestion, ECG, HSCT, Abdominal pain, QT, Sepsis, Acute myeloid leukemia, Alkaline phosphatase, Vomiting, Insomnia, AML, Lymphocytopenia, Patient, NE, Physician, Risk, Hypokalemia, Daiichi Sankyo, Anemia, HR, CR, Mucositis, Nausea, Hypernatremia, FLT3, Fungal infection, Upper respiratory tract infection, Lancet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, Headache, Thrombocytopenia, Nosebleed, Hyperkalemia, TSE, Disease, Pharmaceutical industry, Hypoalbuminemia

VANFLYTA was approved by the FDA on July 20, 2023 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive as detected by an FDA-approved test.

Key Points: 
  • VANFLYTA was approved by the FDA on July 20, 2023 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive as detected by an FDA-approved test.
  • The results of QuANTUM-First were published in The Lancet .1
    The safety of VANFLYTA was evaluated in 265 patients with newly diagnosed FLT3-ITD positive AML who received VANFLYTA once daily (35.4 mg with chemotherapy, 26.5 to 53 mg as maintenance) in the QuANTUM-First trial.
  • Daiichi Sankyo is committed to ensuring that patients in the U.S. who are prescribed VANFLYTA can access the medication and receive appropriate financial support.
  • Provider and patient support and information regarding distribution, access, and reimbursement are now available through Daiichi Sankyo Access Central by visiting www.DSIAccessCentral.com or calling 1-866-4-DSI-NOW (1-866-437-4669).

Rain Oncology Inc. (RAIN) Shareholders: Contact Robbins LLP for Information Regarding the Rain Oncology Inc. Securities Fraud Class Action

Retrieved on: 
Wednesday, August 2, 2023
LLP, RAIN, Daiichi Sankyo, Viability, MANTRA, Person, Complaint, Motion, Patient, SAN, DD, News, Safety, Pharmaceutical industry, Limited

Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.

Key Points: 
  • Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Rain first licensed milademetan from Daiichi Sankyo Company, Limited, in September 2020 based on positive results from a Phase 1 clinical trial.
  • Instead of conducting additional trials to test the safety and dosing of milademetan, Rain proceeded straight to a Phase 3 clinical trial.

Rain Oncology Inc. Class Action: RAIN Investors Should Contact Robbins LLP if They Suffered Financial Losses in Excess of $100,000

Retrieved on: 
Thursday, July 27, 2023
LLP, RAIN, Daiichi Sankyo, Viability, MANTRA, Person, Complaint, Motion, Patient, SAN, DD, News, Safety, Pharmaceutical industry, Limited

Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.

Key Points: 
  • Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Rain first licensed milademetan from Daiichi Sankyo Company, Limited, in September 2020 based on positive results from a Phase 1 clinical trial.
  • Instead of conducting additional trials to test the safety and dosing of milademetan, Rain proceeded straight to a Phase 3 clinical trial.

ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Retrieved on: 
Thursday, July 27, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, HER2, Survival, ILD, Medicine, Interstitial lung disease, AstraZeneca, PFS, ASCO, Dor, MD, Patient, Daiichi Sankyo, Cancer, ADC, Biliary tract, Society, ORR, Safety, Medical imaging

Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.

Key Points: 
  • Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • The DESTINY-PanTumor02 phase 2 trial is evaluating the efficacy and safety of ENHERTU in patients with previously treated locally advanced, unresectable or metastatic HER2 expressing solid tumors not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and other cancers.
  • These data will be presented at an upcoming medical meeting and will support ongoing discussions with global health authorities.

NEOM joins Startup Creasphere's Program Powered by Plug and Play

Retrieved on: 
Tuesday, July 25, 2023
BIX, Roche, Partnership, Plug and play, Climate change, NEOM, Daiichi Sankyo, Nursing

Established in 2018 by Roche and Plug and Play in Munich, Startup Creasphere is one of the largest hubs for digital health innovation worldwide.

Key Points: 
  • Established in 2018 by Roche and Plug and Play in Munich, Startup Creasphere is one of the largest hubs for digital health innovation worldwide.
  • Startup Creasphere powered by Plug and Play is connecting the key stakeholders in the healthcare industry, offering partners such as NEOM, access to a dynamic ecosystem that encourages co-creation and open innovation between like-minded organizations who are driven to disrupt industry norms and accelerate advances in healthcare.
  • Frederike Rohr, Global Director Startup Creasphere and Head of Munich said: "NEOM is adopting a completely fresh perspective on our international ecosystem.
  • For more information about the Startup Creasphere healthcare innovation program, visit https://startupcreasphere.com/

Rain Oncology Inc. (RAIN) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Rain Oncology Inc. Securities Class Action

Retrieved on: 
Monday, July 24, 2023
Class Action Lawsuit, Professional Services, Legal, LLP, RAIN, Daiichi Sankyo, Viability, MANTRA, Person, Complaint, Motion, Patient, DD, News, Safety, Pharmaceutical industry, Limited

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Rain Oncology Inc. (NASDAQ: RAIN) securities between July 20, 2021 and May 19, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Rain Oncology Inc. (NASDAQ: RAIN) securities between July 20, 2021 and May 19, 2023.
  • Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.
  • What is this Case About: Rain Oncology Inc. (RAIN) Misled Investors Regarding the Viability of its Lead Drug Candidate Milademetan
    According to the complaint, Rain’s lead drug candidate was milademetan, a drug designed to treat dedifferentiated liposarcoma (“DD LPS”).
  • Instead of conducting additional trials to test the safety and dosing of milademetan, Rain proceeded straight to a Phase 3 clinical trial.

Senda Biosciences Appoints Igor Matushansky as Chief Medical Officer

Retrieved on: 
Monday, July 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Columbia University, Memorial Sloan Kettering Cancer Center, Gene, Sarcoma, Columbia University Irving Medical Center, Arenavirus, Weill Cornell Medical Center, Doctor of Philosophy, Molecular biology, Weill Cornell Medicine, Flagship Pioneering, Novartis, MD, Patient, NewYork-Presbyterian Hospital, Daiichi Sankyo, Cell, Albert Einstein College of Medicine, Pharmaceutical industry, Annual Review of Cancer Biology, IND

Senda Biosciences, Inc. , a Flagship Pioneering company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Senda Biosciences, Inc. , a Flagship Pioneering company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.
  • Dr. Matushansky will also serve as an Oncology Senior Advisor for Pioneering Medicines, a unit within Flagship Pioneering.
  • “I’m delighted to welcome Igor on board as Senda’s first Chief Medical Officer, as we accelerate our efforts to build out our groundbreaking pipeline of programmable medicines,” said Guillaume Pfefer, Ph.D., Chief Executive Officer, Senda Biosciences and CEO-Partner, Flagship Pioneering.
  • “I’m delighted to join the exceptionally talented team at Senda,” said Dr. Matushansky.